The attacks come after state and local ransomware attacks in New York, Louisiana, Maryland and Florida resulted in the loss of significant sums.Technologyread more
China's pursuit of the Middle East may spur growth in the Islamic finance sector.World Economyread more
Twitter and Facebook have suspended accounts believed to be tied to a state-backed disinformation campaign originating from inside China.Technologyread more
United States Steel Corp will temporarily lay off hundreds of workers at its Great Lakes facility in Michigan in coming weeks, according to a filing the steelmaker made with...US Marketsread more
The report comes as Trump in recent days has lashed out over media reports about growing recession fears.Politicsread more
Beijing will lower borrowing costs for companies, but that may not boost the economy as much as some hope.China Economyread more
Stocks are bouncing higher but could be trapped in a range longer term, until there's a resolution of the trade wars.Market Insiderread more
Stocks in Asia edged higher Tuesday morning as investors await the release of minutes from the Reserve Bank of Australia's July meeting. The People's Bank of China is also set...Asia Marketsread more
Powell will have the opportunity if not to walk back the "midcycle" assessment then to at least provide some further explanation about what it means.Economyread more
Apple has spent more than $6 billion on original TV shows and movies for its forthcoming Apple TV+ service, according to a Financial Times report on Monday.Technologyread more
The Business Roundtable, led by Jamie Dimon, gives a new definition of the "purpose of a corporation."Marketsread more
Dealmaking hit an eight-year high in the first quarter as the cost of doing deals remains low and companies are chasing organic growth, the co-president of private equity firm THL Partners said Wednesday.
Total announced mergers and acquisitions reached $902.2 billion in Q1, the highest level since 2007. Deals valued at $1 billion or more accounted for 69 percent of all mergers and acquisitions volume in the first quarter.
Another factor is that big players see stability on the horizon, THL's Scott Sperling said on CNBC's "Squawk Box."
"I think it's a forward-looking barometer in the sense that people engage in more M&A when they have an expectation of either stability or better growth going forward," he said. "One of the things you've seen is a level of comfort among large strategic players with this stability they're seeing in the marketplace for the foreseeable future."
Two other factors have pumped up dealmaking in 2015, he said, the first being the low cost of undertaking transactions.
"Large strategic players are financing deals at 2 percent interest rates. Obviously the math works really well at reasonably high multiples from a stock accretion perspective if you can do that," he said.
Companies are also striking deals because organic growth is hard to come by, he added. As a result, these players are looking to buy other companies that have organic growth superior to gains in their own core business.
Sperling said it's a good time for private equity firms to harvest companies. The volume of companies held in private equity portfolios ballooned in recent years because firms held onto them longer than usual due to the recession.
"You're seeing more harvesting in terms of the magnitude perhaps than you would in an ordinary cycle, but it's been a good time to harvest because companies have been fixed, they've been made better and it's time for them to be monetized," he said.
As for whether valuations have gotten too high, particularly in the biotech space, Sperling said many smaller biotechs are being acquired because they have "really important science" that larger players can exploit more aggressively.
"Those are multiples being paid for the science itself, and perhaps for the fact that they've already gone through some of the clinical trial issues that often eliminate other drugs," he said.
Sperling acknowledged it is uncertain how many of those acquisitions would eventually be written down, but he added: "The nature of the tools that we have today to understand both disease states and the nature of the impacts of therapeutics on those disease states is far advanced from even what it was three years ago, and therefore, the probability of success, I believe, is higher in that sector."